studies

head and neck cancer squamous cell cancer (HNSCC), pembrolizumab alone vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-040 (all population), 2018 0.80 [0.65; 0.98] KEYNOTE-040 (CPS >1), 2018 0.74 [0.58; 0.94] KEYNOTE-048 (P vs C ; all population), 2019 0.83 [0.70; 0.99] KEYNOTE-048 (P vs C ; CPS > 1), 2019 0.78 [0.64; 0.96] KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.61 [0.45; 0.83] 0.77[0.70; 0.85]KEYNOTE-040 (all population), 2018, KEYNOTE-040 (CPS >1), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 201950%2,250moderateserious deaths (OS) (extension)detailed resultsKEYNOTE-048 (P vs C ; CPS > 1), 2019 0.74 [0.61; 0.90] KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.58 [0.44; 0.77] 0.67[0.53; 0.85]KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019247%767moderatenot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-040 (all population), 2018 0.96 [0.79; 1.16] KEYNOTE-040 (CPS >1), 2018 1.01 [0.81; 1.26] KEYNOTE-048 (P vs C ; all population), 2019 1.34 [1.13; 1.59] KEYNOTE-048 (P vs C ; CPS > 1), 2019 1.16 [0.96; 1.40] KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.99 [0.75; 1.30] 1.10[0.96; 1.25]KEYNOTE-040 (all population), 2018, KEYNOTE-040 (CPS >1), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019553%2,250moderatenot evaluable objective responses (ORR)detailed resultsKEYNOTE-040 (all population), 2018 1.52 [0.88; 2.62] KEYNOTE-040 (CPS >1), 2018 1.90 [1.04; 3.47] KEYNOTE-048 (P vs C ; all population), 2019 0.36 [0.25; 0.53] KEYNOTE-048 (P vs C ; CPS > 1), 2019 0.44 [0.29; 0.66] KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.11 [0.06; 0.20] 0.55[0.23; 1.31]KEYNOTE-040 (all population), 2018, KEYNOTE-040 (CPS >1), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019594%2,250moderatenot evaluable AE (any grade)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.31 [0.22; 0.44] 0.31[0.22; 0.44]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable AE leading to death (grade 5)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.84 [0.48; 1.48] 0.84[0.48; 1.48]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.36 [0.23; 0.55] 0.36[0.23; 0.55]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable TRAE (any grade)detailed resultsKEYNOTE-040 (all population), 2018 0.33 [0.21; 0.51] KEYNOTE-048 (P vs C ; all population), 2019 0.05 [0.02; 0.09] 0.12[0.02; 0.87]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019296%1,067moderatenot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.24 [0.15; 0.39] KEYNOTE-048 (P vs C ; all population), 2019 0.09 [0.06; 0.13] 0.15[0.06; 0.39]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019290%1,067moderatenot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-040 (all population), 2018 1.92 [0.35; 10.57] KEYNOTE-048 (P vs C ; all population), 2019 0.35 [0.09; 1.34] 0.75[0.14; 3.93]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019257%1,067moderatenot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-040 (all population), 2018 1.20 [0.55; 2.62] 1.20[0.55; 2.62]KEYNOTE-040 (all population), 201810%480NAnot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.28 [0.53; 3.10] 1.28[0.53; 3.10]KEYNOTE-040 (all population), 201810%480NAnot evaluable Acute kidney injury TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] 1.91[0.06; 57.09]KEYNOTE-040 (all population), 201810%480NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] KEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35] 1.42[0.11; 18.53]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 201920%1,067moderatenot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.10 [0.01; 0.81] KEYNOTE-048 (P vs C ; all population), 2019 0.04 [0.01; 0.16] 0.05[0.02; 0.17]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 201920%1,067moderatenot evaluable Arthralgia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.23 [0.03; 2.12] KEYNOTE-048 (P vs C ; all population), 2019 0.16 [0.02; 1.31] 0.19[0.04; 0.88]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 201920%1,067moderatenot evaluable Blood and lymphatic system disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.04 [0.01; 0.31] KEYNOTE-048 (P vs C ; all population), 2019 0.02 [0.01; 0.07] 0.03[0.01; 0.07]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 201920%1,067moderatenot evaluable Blood creatinine increased TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37] 0.95[0.06; 15.29]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 201920%1,067moderatenot evaluable Cardiac disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Chills TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.13; 6.84] 0.96[0.16; 5.54]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 201920%1,067moderatenot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21] KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37] 0.64[0.05; 8.37]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 201920%1,067moderatenot evaluable Cough TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] KEYNOTE-048 (P vs C ; all population), 2019 0.12 [0.01; 0.94] 0.34[0.02; 4.81]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019247%1,067moderatenot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 3.85 [0.43; 34.71] KEYNOTE-048 (P vs C ; all population), 2019 0.19 [0.02; 1.62] 0.85[0.04; 16.24]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019273%1,067moderatenot evaluable Dyspepsia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 3.83 [0.17; 85.33] 3.83[0.17; 85.33]KEYNOTE-040 (all population), 201810%480NAnot evaluable Endocrine disorders TRAE (grade 3-4) detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] KEYNOTE-048 (P vs C ; all population), 2019 5.79 [0.29; 116.06] 3.56[0.38; 33.73]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 201920%1,067moderatenot evaluable Epistaxis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Eye disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.92 [0.35; 10.57] KEYNOTE-048 (P vs C ; all population), 2019 0.25 [0.07; 0.92] 0.64[0.09; 4.64]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019271%1,067moderatenot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.05 [0.00; 0.79] 0.05[0.00; 0.79]KEYNOTE-040 (all population), 201810%480NAnot evaluable Gastritis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed resultsKEYNOTE-040 (all population), 2018 0.35 [0.14; 0.86] KEYNOTE-048 (P vs C ; all population), 2019 0.07 [0.02; 0.23] 0.17[0.03; 0.80]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019278%1,067moderatenot evaluable General disorders and administration site conditions TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.57 [0.23; 1.40] KEYNOTE-048 (P vs C ; all population), 2019 0.19 [0.08; 0.46] 0.33[0.11; 0.97]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019266%1,067moderatenot evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] 1.91[0.06; 57.09]KEYNOTE-040 (all population), 201810%480NAnot evaluable Headache TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21] 0.47[0.02; 14.21]KEYNOTE-040 (all population), 201810%480NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 2.01 [0.07; 60.26] KEYNOTE-048 (P vs C ; all population), 2019 3.85 [0.17; 85.65] 2.86[0.29; 28.34]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 201920%1,082moderatenot evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.06; 15.29] 0.95[0.06; 15.29]KEYNOTE-040 (all population), 201810%480NAnot evaluable Hypersensitivity TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Hypertension TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] KEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35] 1.42[0.11; 18.53]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 201920%1,067moderatenot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35] 1.92[0.06; 57.35]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] 1.91[0.06; 57.09]KEYNOTE-040 (all population), 201810%480NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.31 [0.03; 3.04] 0.31[0.03; 3.04]KEYNOTE-040 (all population), 201810%480NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.16 [0.01; 3.15] 0.16[0.01; 3.15]KEYNOTE-040 (all population), 201810%480NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] KEYNOTE-048 (P vs C ; all population), 2019 0.31 [0.06; 1.57] 0.37[0.08; 1.63]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 201920%1,067moderatenot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.07 [0.00; 1.17] KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47] 0.04[0.01; 0.32]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 201920%1,067moderatenot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21] 0.47[0.02; 14.21]KEYNOTE-040 (all population), 201810%480NAnot evaluable Metabolism and nutrition disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.40 [0.10; 1.57] KEYNOTE-048 (P vs C ; all population), 2019 0.26 [0.14; 0.49] 0.28[0.16; 0.50]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 201920%1,067moderatenot evaluable Mucosal inflammation TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.19 [0.02; 1.61] KEYNOTE-048 (P vs C ; all population), 2019 0.13 [0.03; 0.58] 0.15[0.04; 0.50]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 201920%1,067moderatenot evaluable Musculoskeletal and connective tissue disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] 1.91[0.06; 57.09]KEYNOTE-040 (all population), 201810%480NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Myocarditis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37] 0.96[0.02; 48.37]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.48 [0.02; 14.29] 0.48[0.02; 14.29]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21] KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47] 0.10[0.01; 1.53]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019236%1,067moderatenot evaluable Nephritis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 3.85 [0.17; 85.65] 3.85[0.17; 85.65]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Nervous system disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.47 [0.04; 5.26] 0.47[0.04; 5.26]KEYNOTE-040 (all population), 201810%480NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.04 [0.01; 0.33] KEYNOTE-048 (P vs C ; all population), 2019 0.01 [0.00; 0.11] 0.02[0.00; 0.13]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019214%1,067moderatenot evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37] 0.96[0.02; 48.37]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Pancytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.16 [0.01; 3.15] 0.16[0.01; 3.15]KEYNOTE-040 (all population), 201810%480NAnot evaluable Paraesthesia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Peripheral oedema TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] 1.91[0.06; 57.09]KEYNOTE-040 (all population), 201810%480NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.06; 15.29] KEYNOTE-048 (P vs C ; all population), 2019 2.42 [0.46; 12.55] 1.89[0.46; 7.82]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 201920%1,067moderatenot evaluable Pruritic rash TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Pruritus generalised TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.24 [0.01; 5.27] 0.24[0.01; 5.27]KEYNOTE-040 (all population), 201810%480NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Rash TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.06; 15.29] KEYNOTE-048 (P vs C ; all population), 2019 0.11 [0.02; 0.47] 0.23[0.03; 1.77]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019246%1,067moderatenot evaluable Renal and urinary disorders TRAE (grade 3-4) detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] 1.91[0.06; 57.09]KEYNOTE-040 (all population), 201810%480NAnot evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed resultsKEYNOTE-040 (all population), 2018 1.44 [0.40; 5.16] 1.44[0.40; 5.16]KEYNOTE-040 (all population), 201810%480NAnot evaluable Sepsis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.24 [0.01; 5.27] 0.24[0.01; 5.27]KEYNOTE-040 (all population), 201810%480NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.54 [0.15; 1.86] KEYNOTE-048 (P vs C ; all population), 2019 0.29 [0.11; 0.73] 0.36[0.17; 0.76]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 201920%1,067moderatenot evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed resultsKEYNOTE-040 (all population), 2018 0.31 [0.08; 1.15] 0.31[0.08; 1.15]KEYNOTE-040 (all population), 201810%480NAnot evaluable Skin exfoliation TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Stevens-Johnson syndrome TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Stomatitis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.08 [0.01; 0.65] KEYNOTE-048 (P vs C ; all population), 2019 0.05 [0.00; 0.80] 0.07[0.01; 0.36]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 201920%1,067moderatenot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.09 [0.01; 1.72] KEYNOTE-048 (P vs C ; all population), 2019 0.04 [0.00; 0.27] 0.05[0.01; 0.26]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 201920%1,067moderatenot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37] 0.96[0.02; 48.37]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Uveitis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37] 0.96[0.02; 48.37]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Vascular disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.09 [0.01; 1.73] 0.09[0.01; 1.73]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Weight decreased TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.06; 15.37] 0.95[0.10; 9.21]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 201920%1,067moderatenot evaluable Abdominal pain AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.19 [0.02; 1.62] 0.19[0.02; 1.62]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Acute kidney injury AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 1.93 [0.35; 10.60] 1.93[0.35; 10.60]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Anaemia AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.24 [0.13; 0.44] 0.24[0.13; 0.44]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Asthenia AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.31 [0.08; 1.16] 0.31[0.08; 1.16]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Back pain AE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Blood and lymphatic system disorders AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.10 [0.06; 0.18] 0.10[0.06; 0.18]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.28 [0.08; 1.03] 0.28[0.08; 1.03]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.23 [0.05; 1.11] 0.23[0.05; 1.11]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Dizziness AE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 2.26 [0.58; 8.83] 2.26[0.58; 8.83]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Fatigue AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.60 [0.26; 1.42] 0.60[0.26; 1.42]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Febrile neutropenia AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47] 0.03[0.00; 0.47]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable Gastrointestinal disorders AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.33 [0.20; 0.56] 0.33[0.20; 0.56]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-05-28 22:25 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 6,275,106,104,105,276,103,277,102,109,278,101,192,114 - treatments: 359,575,577,576,869

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons